The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for T-cell-based immunotherapy of pediatric sarcomas?
S. Ramakrishna
No relevant relationships to disclose
S. Gottschalk
No relevant relationships to disclose
R. Morgan
No relevant relationships to disclose
G. Dotti
No relevant relationships to disclose
M. K. Brenner
No relevant relationships to disclose
R. Orentas
No relevant relationships to disclose
C. Mackall
No relevant relationships to disclose